Bioventus (BVS) EBIT (2020 - 2026)

Bioventus has reported EBIT for 7 years, with the latest figure at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 72.85% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $57.5 million (up 477.09% YoY), and the FY2025 full-year result was $54.0 million, up 455.22% from the prior year.
• EBIT for Q1 2026 stood at $8.4 million, down from $19.5 million in the prior quarter.
• The five-year high for EBIT was $19.5 million in Q4 2025, with the low at -$126.8 million in Q4 2022.
• Historically, EBIT has averaged -$11.9 million across 5 years, with a median of $3.6 million in 2024.
• Annual changes were most pronounced in 2022 — EBIT slumped 12014.52% — and 2024, when it jumped 561.2%.
• Bioventus' EBIT stood at -$15.6 million in 2022, then jumped by 107.45% to $1.2 million in 2023, then jumped by 561.2% to $7.7 million in 2024, then surged by 152.97% to $19.5 million in 2025, then sank by 56.81% to $8.4 million in 2026.
• The last three EBIT figures came in at $8.4 million (Q1 2026), $19.5 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.